Data protection Impressum

Pharma

Two high-potential start-ups from Western Switzerland, HAYA Therapeutics and Neural Concept, have been named among the World Economic Forum’s 100 Technology Pioneers of 2025.

Two Lausanne-based start-ups named WEF Technology Pioneers in 2025

30 June 2025

Superlab Suisse will open a new laboratory at Campus Biotech in Geneva in January 2026, strengthening the region’s innovation infrastructure for life sciences start-ups.

Superlab expands to Geneva with new lab at Campus Biotech

25 June 2025

Launched in Hamburg, the ORYL F1 marks a new milestone for EPFL spin-off ORYL Photonics, combining speed, precision, and sustainability for drug development.

ORYL Photonics launches breakthrough solubility and aggregation measurement platform

24 June 2025

In this episode of Getting Serious with Woody Wade, we sit down with André Hoffmann, Vice Chairman of Roche and a leading voice in sustainable business, to explore how companies, both large and small, can become forces for long-term prosperity and ecological regeneration.

How Business Can Regenerate the Planet (A Conversation with André Hoffmann)

16 June 2025

Top Stories Western Switzerland

Top Stories from Western Switzerland (May 2025)

28 May 2025

Western Switzerland is rapidly becoming a hotspot for biomanufacturing and life sciences companies, thanks to its strong infrastructure, skilled talent, and business-friendly policies. Yassin Nahi, GGBa (Greater Geneva Bern area) Life Science Director, shares how the region's research hubs, academic institutions, and regulatory support make it an ideal location for companies in this sector.

Why Switzerland

Why Western Switzerland for Biomanufacturing and Life Sciences Companies: an interview with expert Yassin Nahi

Lausanne-based biotech ReproNovo has secured USD 65 million to advance Phase 2 trials for novel therapies in male infertility and women’s reproductive health.

ReproNovo raises USD 65 million to advance trials in reproductive health

21 May 2025

HAYA Therapeutics, a precision medicine company based at Biopôle in Lausanne, has closed a USD 65 million Series A funding round to accelerate the clinical development of its RNA-guided therapies and expand its regulatory genome platform.

HAYA Therapeutics raises USD 65 million to advance RNA-guided therapies for chronic disease

12 May 2025

The latest edition of the Swiss Biotech Report underscores the continued growth and resilience of Switzerland’s biotech sector, attributing success to strong international collaborations and innovative advancements that promise to reshape healthcare worldwide.

The Swiss biotech industry: building resilience through global alliances

6 May 2025

From clinical research to international leadership, Incyte’s steady growth in Western Switzerland showcases the region’s strength in biopharmaceutical innovation.

Incyte, a key player in Western Switzerland’s biopharmaceutical innovation landscape

1 2 3 4 5 … 14